Safe and effective application of anti-TNF- in a patient infected with HIV and concomitant Crohn's disease
- 1 November 2006
- Vol. 55 (11), 1670-1671
- https://doi.org/10.1136/gut.2006.101386
Abstract
CD causes an increase in tumour necrosis factor α (TNF-α) that seems to play a fundamental role in the condition. Thus anti-TNF-α therapies represent a step forward in the management of CD.4 Elevated TNF-α levels are also observed during all stages of HIV, and consequently the use of anti-TNF-α agents has been also suggested for HIV patients.5 To date, three controlled trials of anti-TNF-α based therapies6– , 8 in HIV patients have been reported. Each study registered …Keywords
This publication has 8 references indexed in Scilit:
- A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosisAIDS, 2004
- Short Communication: Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factorα, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2AIDS Research and Human Retroviruses, 2002
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionThe New England Journal of Medicine, 1998
- Inhibition of Immunoreactive Tumor Necrosis Factor- by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1996
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Accelerated course of human immunodeficiency virus infection after tuberculosis.American Journal of Respiratory and Critical Care Medicine, 1995
- Crohn's ileitis in a patient with longstanding HIV infection.1994
- [Subclinical Crohn disease in acquired immunodeficiency syndrome].1993